Ryan M. Cox
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ryan M. Cox has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Surena Namdari
Rothman Orthopaedic Institute
8 shared publications Mark D. Lazarus
3 shared publicationsSurena Namdari
3 shared publications- Daniel E. Davis
Rothman Orthopaedic Institute, Philadelphia, PA, USA
2 shared publications - Daniel E. Goltz.
Rothman Orthopaedics Florida at AdventHealth, Orlando, FL, USA
2 shared publications Gerald R. Williams
Department of Orthopaedic Surgery, The Rothman Orthopaedic Institute at Thomas Jefferson University, Philadelphia, PA, USA
2 shared publications
Latest Publications
- 26 February 2026
- Published by SAGE Publications in Shoulder & Elbow
Comparison of 5-year results of hemiarthroplasty versus anatomic total shoulder arthroplasty in patients under 40 years old
Background: End-stage glenohumeral joint arthritis in young patients is difficult to manage due to increased physical demands and the need for prolonged implant longevity. Because of this, many surgeons prefer hemiarthroplasty (HA) over traditional anatomic total shoulder arthroplasty (TSA). This study aimed to compare the implant survivorship and patient-reported outcomes of HA versus TSA performed in patients under 40 years old. Methods: This study was a retrospective analysis of patients at a single institution who underwent HA or TSA at age 40 or younger with at least 5-year follow-up from their index surgery or until documented implant failure. Preoperative data collected included demographic variables, number of prior surgeries, and indication for shoulder arthroplasty. Postoperative data collected included implant survivorship, range of motion, pain visual analoge scale (VAS), American Shoulder and Elbow Surgeons (ASES), and Single Assessment Numeric Evaluation (SANE) scores. Results: The final analysis included 18 patients who underwent HA and 45 patients who underwent TSA. The average follow-up period was 7.8 ± 2.8 years among HA patients versus 9.6 ± 3.9 among TSA patients. Post-traumatic arthritis was the most common indication for both HA (39%) and TSA groups (47%). Five (21.7%) HA patients underwent revision, most commonly for glenoid wear. Thirteen (28.9%) TSA patients were revised, most commonly for rotator cuff failure. Among revision cases, the mean time to revision was 6.2 ± 5.5 years for HA patients and 8.6 ± 6.0 years for TSA patients ( p = 0.521). There were no significant differences between the cohorts for revision rate ( p = 0.577) and the 5-year Kaplan–Meier survival rate (88.9% for HA vs. 93.3% for TSA, p = 0.364). There were no significant differences in postoperative ASES, SANE, and VAS between the two cohorts ( p > 0.05). Conclusion: HA and TSA yielded comparable implant survivorship and patient outcomes in patients under the age of 40 at 5-year follow-up. Although glenoid arthrosis remains a concern, HA should not be excluded as a surgical choice for younger patients and should be considered on a case-by-case basis. Level of Evidence: Level III—Retrospective Cohort Study
- 26 February 2026
- Published by SAGE Publications in Shoulder & Elbow
Comparison of 5-year results of hemiarthroplasty versus anatomic total shoulder arthroplasty in patients under 40 years old
Background: End-stage glenohumeral joint arthritis in young patients is difficult to manage due to increased physical demands and the need for prolonged implant longevity. Because of this, many surgeons prefer hemiarthroplasty (HA) over traditional anatomic total shoulder arthroplasty (TSA). This study aimed to compare the implant survivorship and patient-reported outcomes of HA versus TSA performed in patients under 40 years old. Methods: This study was a retrospective analysis of patients at a single institution who underwent HA or TSA at age 40 or younger with at least 5-year follow-up from their index surgery or until documented implant failure. Preoperative data collected included demographic variables, number of prior surgeries, and indication for shoulder arthroplasty. Postoperative data collected included implant survivorship, range of motion, pain visual analoge scale (VAS), American Shoulder and Elbow Surgeons (ASES), and Single Assessment Numeric Evaluation (SANE) scores. Results: The final analysis included 18 patients who underwent HA and 45 patients who underwent TSA. The average follow-up period was 7.8 ± 2.8 years among HA patients versus 9.6 ± 3.9 among TSA patients. Post-traumatic arthritis was the most common indication for both HA (39%) and TSA groups (47%). Five (21.7%) HA patients underwent revision, most commonly for glenoid wear. Thirteen (28.9%) TSA patients were revised, most commonly for rotator cuff failure. Among revision cases, the mean time to revision was 6.2 ± 5.5 years for HA patients and 8.6 ± 6.0 years for TSA patients ( p = 0.521). There were no significant differences between the cohorts for revision rate ( p = 0.577) and the 5-year Kaplan–Meier survival rate (88.9% for HA vs. 93.3% for TSA, p = 0.364). There were no significant differences in postoperative ASES, SANE, and VAS between the two cohorts ( p > 0.05). Conclusion: HA and TSA yielded comparable implant survivorship and patient outcomes in patients under the age of 40 at 5-year follow-up. Although glenoid arthrosis remains a concern, HA should not be excluded as a surgical choice for younger patients and should be considered on a case-by-case basis. Level of Evidence: Level III—Retrospective Cohort Study
- 12 January 2026
- Published by SAGE Publications in Shoulder & Elbow
Outcomes following manufacturer-mismatched implants in primary and revision shoulder arthroplasty
In reverse total shoulder arthroplasty (RSA), surgeons predominantly use components from the same manufacturer. In certain situations, it may be advantageous to “mismatch” components. There is a lack of literature investigating outcomes following manufacturer-mismatched implants. Therefore, the purpose of this study was to evaluate the outcomes following RSA with manufacturer-mismatched implants. All primary or revision RSAs between 2013 to 2021 with manufacturer-mismatched glenoid and humeral components was performed. Data collected included demographic variables, postoperative function, and complications. Totally 85 patients underwent RSA with manufacturer-mismatched implants. Sixty-three were primary cases (74%) and 22 (26%) were revision cases. The mean age was 70.2 ± 8.8, and 20 (24%) were male. The mean follow-up was 47.8 (range: 24–114 months). In primary cases the mean ASES score was 79.1 ± 21.3, SANE score of 75 ± 25.4, and VAS pain score of 1.8 ± 2.5. For revisions, the mean ASES score was 61.2 ± 25.9, SANE score of 50 ± 31.9, and VAS pain score of 3.2 ± 2.9. These are comparable to historical controls. Fourteen (16.4%) patients sustained a postoperative complication, six (7.1%) underwent a reoperation. Our results demonstrate that manufacturer-mismatching has comparable postoperative function, complications, and reoperation rates to the reported literature. Level of evidence: III
- 12 January 2026
- Published by SAGE Publications in Shoulder & Elbow
Outcomes following manufacturer-mismatched implants in primary and revision shoulder arthroplasty
In reverse total shoulder arthroplasty (RSA), surgeons predominantly use components from the same manufacturer. In certain situations, it may be advantageous to “mismatch” components. There is a lack of literature investigating outcomes following manufacturer-mismatched implants. Therefore, the purpose of this study was to evaluate the outcomes following RSA with manufacturer-mismatched implants. All primary or revision RSAs between 2013 to 2021 with manufacturer-mismatched glenoid and humeral components was performed. Data collected included demographic variables, postoperative function, and complications. Totally 85 patients underwent RSA with manufacturer-mismatched implants. Sixty-three were primary cases (74%) and 22 (26%) were revision cases. The mean age was 70.2 ± 8.8, and 20 (24%) were male. The mean follow-up was 47.8 (range: 24–114 months). In primary cases the mean ASES score was 79.1 ± 21.3, SANE score of 75 ± 25.4, and VAS pain score of 1.8 ± 2.5. For revisions, the mean ASES score was 61.2 ± 25.9, SANE score of 50 ± 31.9, and VAS pain score of 3.2 ± 2.9. These are comparable to historical controls. Fourteen (16.4%) patients sustained a postoperative complication, six (7.1%) underwent a reoperation. Our results demonstrate that manufacturer-mismatching has comparable postoperative function, complications, and reoperation rates to the reported literature. Level of evidence: III
- 5 December 2025
- Published by Elsevier in Seminars in Arthroplasty: JSES
- Vol. 36 (1)
Shoulder arthroplasty in patients with prior hip, knee, or shoulder periprosthetic joint infection: a safe option?
- 5 December 2025
- Published by Elsevier in Seminars in Arthroplasty: JSES
- Vol. 36 (1)
Shoulder arthroplasty in patients with prior hip, knee, or shoulder periprosthetic joint infection: a safe option?
- 7 June 2024
- Published by Elsevier in Journal of Shoulder and Elbow Surgery
- Vol. 33 (12) , 2596-2603
Effects of socioeconomic burden on opioid use following total shoulder arthroplasty
- 7 June 2024
- Published by Elsevier in Journal of Shoulder and Elbow Surgery
- Vol. 33 (12) , 2596-2603
Effects of socioeconomic burden on opioid use following total shoulder arthroplasty
- 18 March 2024
- Published by SAGE Publications in Shoulder & Elbow
- Vol. 17 (2) , 182-188
Management of periprosthetic humerus fractures after shoulder arthroplasty
Background: The purpose of this retrospective study was to analyze time to fracture union, complications, and outcomes of postoperative periprosthetic humerus fractures after primary shoulder arthroplasty. Methods: Retrospective review of patients who sustained a postoperative periprosthetic humerus fracture after primary shoulder arthroplasty at a single institution. Fractures were classified according to the Worland Classification system. Both non-operatively and operatively treated patients were included. The primary study outcomes were time to union and complications. Results: There were 46 patients who sustained a postoperative periprosthetic humerus fracture after primary shoulder arthroplasty, 18 were treated non-operatively and 28 were treated operatively. There were seven (25%) patients who underwent surgery after failed non-operative management. There was only one (2.2%) patient who had a nonunion at final follow-up. The average American Shoulder and Elbow Surgeons Shoulder Score, Single Assessment Numeral Evaluation, and visual analog scale pain scores were 73.5 ± 22.7, 66.5 ± 23.1, and 2.2 ± 2.4, respectively. Conclusion: There was a high rate of union for both non-operatively and operatively treated periprosthetic fractures. However, there was a high rate of cross-over from non-operative to operative treatment and a high complication rate for both cohorts. For properly indicated patients, non-operative and operative treatment can result in satisfactory patient outcomes.
- 18 March 2024
- Published by SAGE Publications in Shoulder & Elbow
- Vol. 17 (2) , 182-188
Management of periprosthetic humerus fractures after shoulder arthroplasty
Background: The purpose of this retrospective study was to analyze time to fracture union, complications, and outcomes of postoperative periprosthetic humerus fractures after primary shoulder arthroplasty. Methods: Retrospective review of patients who sustained a postoperative periprosthetic humerus fracture after primary shoulder arthroplasty at a single institution. Fractures were classified according to the Worland Classification system. Both non-operatively and operatively treated patients were included. The primary study outcomes were time to union and complications. Results: There were 46 patients who sustained a postoperative periprosthetic humerus fracture after primary shoulder arthroplasty, 18 were treated non-operatively and 28 were treated operatively. There were seven (25%) patients who underwent surgery after failed non-operative management. There was only one (2.2%) patient who had a nonunion at final follow-up. The average American Shoulder and Elbow Surgeons Shoulder Score, Single Assessment Numeral Evaluation, and visual analog scale pain scores were 73.5 ± 22.7, 66.5 ± 23.1, and 2.2 ± 2.4, respectively. Conclusion: There was a high rate of union for both non-operatively and operatively treated periprosthetic fractures. However, there was a high rate of cross-over from non-operative to operative treatment and a high complication rate for both cohorts. For properly indicated patients, non-operative and operative treatment can result in satisfactory patient outcomes.
- 18 November 2023
- Published by Elsevier in Journal of Shoulder and Elbow Surgery
- Vol. 33 (6) , 1306-1312
Management of proximal humerus bone loss with allograft prosthetic composite technique in shoulder arthroplasty
- 18 November 2023
- Published by Elsevier in Journal of Shoulder and Elbow Surgery
- Vol. 33 (6) , 1306-1312
Management of proximal humerus bone loss with allograft prosthetic composite technique in shoulder arthroplasty
- 1 June 2023
- Published by Wolters Kluwer Health in JBJS Reviews
- Vol. 11 (6)
Humeral Head Avascular Necrosis
» Avascular necrosis (AVN) of the humeral head is the result of ischemic injury to the epiphyseal bone leading to humeral head collapse and arthritis. » Common causes include trauma, chronic corticosteroid use, or systemic disease processes, such as sickle cell disease, systemic lupus erythematosus, or alcohol abuse. » Nonoperative treatment consists of risk factor management, physical therapy, anti-inflammatory medications, and activity modification. » Surgical treatment options include arthroscopic debridement, core decompression, vascularized bone grafts, and shoulder arthroplasty.
- 1 June 2023
- Published by Wolters Kluwer Health in JBJS Reviews
- Vol. 11 (6)
Humeral Head Avascular Necrosis
» Avascular necrosis (AVN) of the humeral head is the result of ischemic injury to the epiphyseal bone leading to humeral head collapse and arthritis. » Common causes include trauma, chronic corticosteroid use, or systemic disease processes, such as sickle cell disease, systemic lupus erythematosus, or alcohol abuse. » Nonoperative treatment consists of risk factor management, physical therapy, anti-inflammatory medications, and activity modification. » Surgical treatment options include arthroscopic debridement, core decompression, vascularized bone grafts, and shoulder arthroplasty.
- 18 February 2023
- Published by Elsevier in Journal of Shoulder and Elbow Surgery
- Vol. 32 (6) , S1-S7
Shoulder periprosthetic joint infection is associated with increased mortality
- 18 February 2023
- Published by Elsevier in Journal of Shoulder and Elbow Surgery
- Vol. 32 (6) , S1-S7
Shoulder periprosthetic joint infection is associated with increased mortality
- 23 November 2022
- Published by Elsevier in Journal of Shoulder and Elbow Surgery
- Vol. 32 (3) , 662-670
The impact of elective surgery restrictions during the COVID-19 (coronavirus disease 2019) pandemic on shoulder and elbow surgery: patient perceptions
- 23 November 2022
- Published by Elsevier in Journal of Shoulder and Elbow Surgery
- Vol. 32 (3) , 662-670
The impact of elective surgery restrictions during the COVID-19 (coronavirus disease 2019) pandemic on shoulder and elbow surgery: patient perceptions